Cintas Corp: enters merger agreement with UniFirst

What happened

• Cintas Corp filed an Form 8-K on Oct 6, 2026 reporting that on Mar 10, 2026 Cintas entered into an Agreement and Plan of Merger with UniFirst Corporation, Bruin Merger Sub I, Inc. (Merger Sub Inc.) and Bruin Merger Sub II, LLC (Merger Sub LLC).
• The Merger Agreement provides that, subject to closing conditions, Merger Sub Inc. will merge into UniFirst (the First Merger), after which UniFirst will be a wholly owned subsidiary of Cintas, and then UniFirst will merge into Merger Sub LLC (the Second Merger), after which Merger Sub LLC will be a wholly owned subsidiary of Cintas.
• The filing also reported regulatory developments and certifications to the U.S. Federal Trade Commission (FTC) and the Canadian Competition Bureau (CCB), and that Cintas “continues to expect that the Mergers will close prior to the end of calendar year 2026, subject to the satisfaction or waiver of customary closing conditions.”

Key details

• Merger Agreement dated Mar 10, 2026 between Cintas and UniFirst with two wholly owned Cintas merger subsidiaries (Merger Sub Inc. and Merger Sub LLC).
• FTC Second Request received Jun 11, 2026; Cintas and UniFirst certified substantial compliance with the Second Request on Oct 2, 2026 and entered a timing agreement with the FTC not to consummate the Mergers prior to Dec 11, 2026 unless the FTC closes its investigation earlier in writing.
• CCB Supplementary Information Request received Jul 2, 2026; Cintas and UniFirst certified completion of their response to the SIR on Sep 29, 2026.
• Cintas continues to expect closing prior to the end of calendar year 2026, subject to satisfaction or waiver of customary closing conditions.

Why it may matter

• This Item 8.01 report covers the Agreement and Plan of Merger between Cintas and UniFirst and provides updates on regulatory reviews by the FTC and the CCB.
• The filing contains forward-looking statements and lists potential risks and uncertainties related to the Transaction, including regulatory approvals and integration risks.
• The filing does not show why the insider traded or why the company acted.